logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Principia Biopharma Inc.

USPTO Granted Patents = 56


Trademarks = 2

Forward Citations = 375

Loading Chart...
Loading Chart...

38 inventors (with patents filed for the assignee):

goldMedal Kenneth Albert Brameld (17 out of 27 patents)

silverMedal David Michael Goldstein (16 out of 62 patents)

bronzeMedal Mohammad Reza Masjedizadeh (14 out of 14 patents)

4.  Erik J Verner (12 out of 83 patents)

5.  Timothy D Owens (10 out of 31 patents)

6.  Jiang Zhu (7 out of 7 patents)

7.  Pasit Phiasivongsa (7 out of 7 patents)

8.  Tim Owens (6 out of 6 patents)

9.  Steven Gourlay (6 out of 6 patents)

10.  Kolbot By (6 out of 7 patents)

11.  Yan Lou (5 out of 74 patents)

12.  Claire Langrish (3 out of 3 patents)

13.  Katherine A Chu (2 out of 3 patents)

14.  Dolca Thomas (2 out of 2 patents)

15.  Wu Lin (2 out of 7 patents)


Core Competencies:
Tyrosine Kinase Inhibitors
Immunoproteasome Inhibitors
FGFR Inhibitors
Quinolone Derivatives
Pyrazolopyrimidine Compounds
Modified Release Formulations
Solid Forms
Crystalline Forms
Substituted Pyrazolo Compounds
Benzimidazole Derivatives
Treatment of Pemphigus

56 patents:

1. 12766146 - Salts and solid form of a BTK inhibitor (2026-10-20),
2. 12751954 - Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds (2026-10-06),
3. 12673953 - Process for preparing an amorphous form of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2026-07-07),
4. 12636280 - Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (RMS) (2026-05-26),
5. 12624030 - 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof (2026-05-12),
6. 12410176 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2025-09-09),
7. 12336999 - Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl]pent-2-enenitrile (2025-06-24),
8. 12312370 - Immunoproteasome inhibitors (2025-05-27),
9. 12281120 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile (2025-04-21),
10. 12281110 - Processes for preparing an FGFR inhibitor (2025-04-21),
11. 12178818 - Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2024-12-31),
12. 12024531 - Immunoproteasome inhibitors (2024-07-02),
13. 11872229 - Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2024-01-16),
14. 11827656 - Immunoproteasome inhibitors (2023-11-28),
15. 11814390 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2023-11-14),
Company Overview
Principia Biopharma Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative therapies targeting various diseases. The company focuses on tyrosine kinase inhibitors and immunoproteasome inhibitors, leveraging advanced technologies to create effective treatments. Its research encompasses a range of compounds, including FGFR inhibitors, quinolone derivatives, and pyrazolopyrimidine compounds, along with expertise in modified release formulations and solid crystalline forms.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

56 Patents

#26 in South San Francisco, CA

#1,494 in California

#6,362 in US

#12,761 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Principia Biopharma Inc.

Forward Citations = 375

38 inventors:

goldMedal Kenneth Albert Brameld (17 out of 27 patents)

silverMedal David Michael Goldstein (16 out of 62 patents)

bronzeMedal Mohammad Reza Masjedizadeh (14 out of 14 patents)

4.  Erik J Verner (12 out of 83 patents)

5.  Timothy D Owens (10 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Principia Biopharma Inc.. Retrieved from https://idiyas.com/company/principia-biopharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…